| Sign In to gain access to subscriptions and/or personal tools. |
Do we need to adjudicate major clinical events?Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715-7969, grangool{at}mc.duke.edu
University of Pittsburgh IRB, Magee Women's Hospital, Pittsburgh, PA
University of California, San Francisco, CA
AstraZeneca, Molndal, Sweden
BMS, Princeton, NJ
PHRI, Hamilton, ON, Canada
George Institute, Camperdown, Australia
Boehringer Ingelheim
PHRI, Hamilton, ON, Canada
GlaxoSmithKline, King Of Prussia, PA
FDA, Washington, DC
PHRI, Hamilton, ON, Canada Purpose The use of centralized systems to adjudicate clinical events is common in large clinical trials, in spite of relatively little published literature concerning the rationale and justification. The purpose of this manuscript is to review the reasons for central adjudication and to discuss whether trials could be simplified by limiting or streamlining the adjudication process. Methods We reviewed the literature concerning central adjudication and documented the experience of adjudication in several clinical trials. Since definitions for nonfatal events are generally heterogeneous and subjective, one reason for a central process of adjudication is to assist in assuring systematic application of the definition used in the trial. In open-label trials, assuring that the adjudication is done blinded to treatment assignment may provide protection against differential misclassification. Regulatory authorities, including the FDA, derive confidence in the validity of results when central adjudication is performed. The clinical community has become accustomed to a certain amount of adjudication and may criticize trials that lack adjudication. Limitations It is difficult to document the value of adjudication in trials that have reported adjudicated and nonadjudicated event rates and related treatment effects. Making rationale decisions about when and how to adjudicate is hampered by the lack of published study of when and how central adjudication is helpful to improve the quality and validity of trials and at what cost. Conclusions Adjudication has not been shown to improve the ability to determine treatment effects. Thus, adjudication may be overly complex and overused in many large simple trials. The appropriate role of central adjudication — which trials, which outcomes, what methods — deserves scrutiny and further study. Clinical Trials 2008; 5: 56—60. http://ctj.sagepub.com
Clinical Trials, Vol. 5, No. 1,
56-60 (2008) This article has been cited by other articles:
|
||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
